In a significant advancement for cancer immunotherapy, researchers at the Dana-Farber Cancer Institute have demonstrated that CDK2 inhibitors can overcome resistance to immune checkpoint inhibitors. The study, published recently, shows that combining these agents eradicates colorectal and breast cancers in animal models, including triple-negative breast cancer that was previously completely resistant to checkpoint blockade alone. This finding opens a new avenue for treating cancers that have proven difficult to manage with existing immune-based therapies.
The mechanism behind this efficacy involves a dual action. High expression of cyclin E-CDK2 is linked to poor outcomes across at least nine cancer types, including bladder, ovarian, uterine, colorectal, liver, lung, lymphoma, melanoma, and prostate cancer. The research reveals that hyperactive cyclin E-CDK2 phosphorylates BRD4, a protein crucial for gene regulation. This phosphorylation restricts BRD4's chromatin occupancy, which in turn reduces the expression of immune-related genes, antigen processing genes, and interferon-stimulated genes, effectively cloaking the tumor from the immune system.
Beyond sensitizing tumor cells, the study highlights a critical role for dendritic cells. Inhibiting CDK2 not only makes cancer cells more vulnerable to immune attack but also directly enhances dendritic cell number, infiltration, and their ability to present antigens to T cells. This two-pronged approach—targeting both the tumor cell's sensitivity and the immune system's function—represents a sophisticated strategy to reinvigorate the anti-tumor immune response.
Perhaps most compelling is the clinical relevance of these findings. The researchers identified CDK2 inhibitors, such as tegtociclib, which are already in clinical trials for cyclin E-amplified ovarian and breast cancer. The study suggests that these agents could have substantially broader applicability when paired with immunotherapy, potentially benefiting a wide range of cancer patients who currently do not respond to checkpoint inhibitors.
Why it matters: By simultaneously sensitizing tumor cells and activating dendritic cell-mediated immunity, CDK2 inhibitors address the dual barriers of immunotherapy resistance. This approach could transform the treatment landscape for nine major cancer types currently plagued by poor responses to existing therapies.
